{
    "id": 14103,
    "fullName": "CCND2 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "CCND2 amp indicates an increased number of copies of the CCND2 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 894,
        "geneSymbol": "CCND2",
        "terms": [
            "CCND2",
            "KIAK0002",
            "MPPH3"
        ]
    },
    "variant": "amp",
    "createDate": "11/20/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7248,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cancer cell lines harboring CCND2 amplification demonstrated sensitivity to treatment with Abemaciclib (LY2835219) in culture and in vivo, resulting in increased apoptosis, senescence, and tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 3104).",
            "molecularProfile": {
                "id": 14359,
                "profileName": "CCND2 amp"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3968,
                    "pubMedId": null,
                    "title": "Abstract 3104: Molecular features that determine the sensitivity of cancer cells to abemaciclib, an inhibitor of CDK4 and CDK6",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/3104.abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 14359,
            "profileName": "CCND2 amp",
            "profileTreatmentApproaches": [
                {
                    "id": 7092,
                    "name": "CDK4/6 Inhibitor",
                    "profileName": "CCND2 amp"
                }
            ]
        },
        {
            "id": 32263,
            "profileName": "CCND2 amp RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}